By Christy Santhosh and Ahmed Aboulenein

WASHINGTON (Reuters) -The U.S. Food and Drug Administration said on Monday it would remove the strictest “black box” warnings from hormone therapies used to treat menopause symptoms, a move that may boost access to treatments long shunned by patients and doctors over safety fears.

FDA Commissioner Marty Makary said the decision follows an extensive review of scientific literature, input from an expert panel in July, and a public comment period.

“After 23 years of dogma, the FDA today is announcing that we are going to stop the fear machine steering women away from this life-changing, even life-saving treatment,” Makary said during a press conference.

“We are listening to women who have been challenging the paternalism of medicine. We are listeni

See Full Page